Compare HSAI & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HSAI | TLX |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | China | Australia |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.3B |
| IPO Year | 2023 | N/A |
| Metric | HSAI | TLX |
|---|---|---|
| Price | $20.52 | $9.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $31.58 | $21.00 |
| AVG Volume (30 Days) | ★ 2.6M | 108.9K |
| Earning Date | 11-11-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.44 | 0.04 |
| Revenue | $385,835,909.00 | ★ $664,225,558.00 |
| Revenue This Year | $55.36 | N/A |
| Revenue Next Year | $46.30 | N/A |
| P/E Ratio | ★ $46.72 | $284.97 |
| Revenue Growth | 43.17 | ★ 55.35 |
| 52 Week Low | $10.01 | $8.76 |
| 52 Week High | $30.85 | $30.36 |
| Indicator | HSAI | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 52.28 | 38.74 |
| Support Level | $19.94 | $9.37 |
| Resistance Level | $20.91 | $10.03 |
| Average True Range (ATR) | 0.89 | 0.25 |
| MACD | 0.42 | -0.00 |
| Stochastic Oscillator | 81.82 | 7.65 |
Hesai Group is engaged in the development, manufacture, and sales of three-dimensional light detection and ranging solutions, or LiDAR. Its LiDAR products enable a broad spectrum of applications across passenger or commercial vehicles with enhanced advanced driver assistance systems, or ADAS, autonomous vehicle fleets providing passenger and freight mobility services, or Autonomous Mobility, and other applications such as last-mile delivery robots, street sweeping robots, and logistics robots in restricted areas, or Robotics. Geographically, the company operates in North America, Mainland China, Europe, and Other regions.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.